Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Gliomas Clinical Trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (78) clinical trials

ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-Nave Subjects with Progressive High Grade Glioma Following Prior Therapy and Subjects with Newly Diagnosed Glioblastoma. ABI-009 will be tested as single agent or in combination with standard therapies

Phase

Olaparib in Treating Patients With Advanced Glioma Cholangiocarcinoma or Solid Tumors With IDH1 or IDH2 Mutations

PRIMARY OBJECTIVE: I. To estimate the overall response rates of olaparib in subjects with recurrent/progressive IDH1/2-mutant solid tumors, who will be recruited to 3 cohorts: a. glioma, b. cholangiocarcinoma, c. other solid malignant tumors. SECONDARY OBJECTIVES: I. To estimate the distribution of progression free survival (PFS) of olaparib in adults ...

Phase

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

PRIMARY OBJECTIVE: I. Determine if selumetinib can result in shrinkage cutaneous neurofibromas. SECONDARY OBJECTIVE: I. Assess the effect of selumetinib on target inhibition in cutaneous neurofibroma(s) excised prior treatment and on treatment with selumetinib for analysis of percent inhibition of phosphorylated ERK (pERK), and changes in phosphorylated AKT (pAKT). EXPLORATORY ...

Phase

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in children and adults. Secondary objectives comprise the efficacy and safety of larotrectinib in different NTRK-tumor types.

Phase

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

Approximately 64 patients with resected, newly-diagnosed WHO Grade IV glioma in which the Methylguanine Methyltransferase (MGMT) is not methylated will be accrued to this study before standard of care radiation therapy (RT) and concurrent TMZ, with the goal of treating 48 patients with dose-intensified temozolomide and pp65 loaded dendritic cell ...

Phase

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

PRIMARY OBJECTIVES: I. To assess the 18 month overall survival rate of pembrolizumab in combination with standard therapy (surgery, external beam radiation therapy and temozolomide [TMZ] chemotherapy) in patients with newly diagnosed glioblastoma multiforme (GBM). SECONDARY OBJECTIVES: I. To assess adverse events (AE) and toxicity profile of pembrolizumab in combination ...

Phase

Protein Phosphatase 2A Inhibitor in Recurrent Glioblastoma

Background Primary gliomas are an incurable disease in spite of aggressive multimodality therapy consisting of craniotomy, irradiation, and chemotherapy. Therapeutic options for patients with recurrent glioma are limited, and there is an unmet need to identify more effective agents. LB100, a water soluble small molecule novel protein phosphatase 2A (PP2A) ...

Phase

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

Dendritic cells (DC) are involved in activating, or turning-on, your body's immune system. Your immune system helps guard your body from germs, viruses, and other threats. Although dendritic cells are very strong, the number of them in the body is not high enough to cause a powerful immune response; therefore, ...

Phase

Low Dose Radiation Therapy for Glioblastoma Multiforme

In vitro and in vivo studies have suggested that low dose fractionated radiation therapy (LDFRT) may be used to potentiate full dose chemotherapy, decreasing the development of resistance found with standard doses of radiation and chemotherapy. This is a nonrandomized, open label, single institution phase II trial with a safety ...

Phase

Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers

Background There are more than 130 identified primary tumors of the central nervous system (CNS). Most have an annual incidence of less than 1000 in the United States. Given the rarity of each of the tumors listed above, there is a paucity of proven therapies. Most of these neoplasms are ...

Phase